Hydrocortisone as co-treatment to prevent neuropsychiatric adverse effects of dexamethasone.

INTERVENTION: Hydrocortisone or placebo as add‐on to dexamethasone. CONDITION: Anxiety, Depression, Cognition, Manic depressive illness, Sleep, Delirium ; ; PRIMARY OUTCOME: The primary parameter is neuropsychiatric adverse effects measured by the Brief Psychiatric Rating Scale (BPRS). SECONDARY OUTCOME: Secondary parameters are neuropsychiatric adverse effects measured with different questionnaires (Hospital Anxiety and Depression Scale, Altman Self‐Rating Mania scale, Positive Affect Negative Affect Scale and Visual Analogue Scales); neurophysiological functioning assessed with different cognitive tests, sleep quality measured with actigraphy and the Leeds Sleep Evaluation Questionnaire (LSEQ) and quality of life with QLQ‐C30+BN20. INCLUSION CRITERIA: ‐ Cranial glioma or meningioma scheduled to undergo surgery (resection + biopsy) ‐ Minimal dose of peri‐operative cumulative dexamethasone exposure of 24mg or more in 6 days ‐ ¡Ý18 years ‐ Good clinical condition; KPS ¡Ý 70 ‐ Life expectancy ¡Ý 6 months ‐ Patients with already low dose dexamethasone are allowed in the study